Andre Kleensang, PhD
- Dr. rer. hum. biol.
- Research Associate
615 N. Wolfe St., W7032
Baltimore, Maryland 21205
+1 410 614 4971
+1 410 614 2871
PhD, Medical University of Lubeck, 2010
Dr. André Kleensang (M) received his university degree in biochemistry in 2001 from the University of Hamburg (Germany). Between 2003 und 2007 he was responsible for the biometrical and bioinformatics support within several genome wide genetic epidemiological studies at the Institute of Medical Biometry and Statistics at the Medical University of Luebeck/Germany. In 2007 he moved to the European Centre for the Validation of Alternative Methods (ECVAM) at the European Commission Joint Research Centre (JRC) where he was involved as a biometrics and bioinformatics specialist in the development and validation of in vitro methods on international level. Since 2008 he worked with the same responsibilities for the systems toxicology unit at ECVAM and was until 2010 appointed member of the Institute for Health and Consumer Protection Scientific Committee of the JRC. Currently he works as Research Associate at Johns Hopkins Center for Alternatives to Animal Testing (CAAT) and is faculty member at the department of Environmental Health Sciences at the Johns Hopkins Bloomberg School of Public Health. His main responsibilities are to combine various data-rich omics approaches to identify pathways of toxicity and developing, implementing and validating novel tools for pathway of toxicity identification. Due to his background in Evidence-based Medicine he supports as well the activities of the Evidence-based Toxicology program.
Journal Articles (peer reviewed)
Kinsner-Ovaskainen A, Maxwell G, Kreysa J, Barroso J, Adriaens E, Alépéé N, Berg N, Bremer S, Coecke S, Comenges JZ, Corvi R, Casati S, Dal Negro G, Marrec-Fairley M, Griesinger C, Halder M, Heisler E, Hirmann D, Kleensang A, Kopp-Schneider A, Lapenna S, Munn S, Prieto P, Schechtman L, Schultz T, Vidal JM, Worth A, Zuang V: Report of the EPAA-ECVAM Workshop on Validation of Integrated Testing Strategies (ITS). Toxicol In Vitro (in press)
Sebastian Hoffmann S, Hothorn L, Edler L, Kleensang A, Suzuki M, Phrakonkham P, Gerhard D: Two new approaches to improve the analysis of BALB/c 3T3 Cell Transformation Assay data. Mutat Res 2012, 744(1):36-41, DOI: 10.1016/j.mrgentox.2011.12.002 (in press) [ISI Journal Impact Factor 2010: 2.94]
König I R, Schumacher J, Hoffmann P, Kleensang A, Ludwig K U, Grimm T, Neuhoff N, Preis M, Roeske D, Warnke A, Propping P, Remschmidt H, Nöthen M, Ziegler A, Müller-Myhsok B, Schulte-Körne G: Mapping for dyslexia and related cognitive trait loci provides strong evidence for further risk genes on chromosome 6p21. Am J Med Genet B 2011, 156(1):36-43, DOI: 10.1002/ajmg.b.31135 [4.16]
* Kleensang A, Alcaïs A, Franke D, Abel L, Müller-Myhsok B, Ziegler A: A Comprehensive Comparison of Quantitative Trait Loci Mapping Methods. Hum Hered 2010, 69(3):202-11, DOI: 10.1159/000289596 [2.34]